Principal Financial Group Inc. cut its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 0.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,603 shares of the biotechnology company’s stock after selling 795 shares during the quarter. Principal Financial Group Inc. owned 0.58% of Enanta Pharmaceuticals worth $4,918,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the company. Arizona State Retirement System grew its stake in shares of Enanta Pharmaceuticals by 3.9% in the fourth quarter. Arizona State Retirement System now owns 5,555 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 208 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Enanta Pharmaceuticals by 8.4% in the fourth quarter. ProShare Advisors LLC now owns 4,808 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 374 shares during the period. State of Tennessee Treasury Department boosted its holdings in Enanta Pharmaceuticals by 3.0% in the fourth quarter. State of Tennessee Treasury Department now owns 13,142 shares of the biotechnology company’s stock valued at $611,000 after purchasing an additional 386 shares during the period. Yousif Capital Management LLC boosted its holdings in Enanta Pharmaceuticals by 2.8% in the first quarter. Yousif Capital Management LLC now owns 16,477 shares of the biotechnology company’s stock valued at $1,173,000 after purchasing an additional 445 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in Enanta Pharmaceuticals by 4.4% in the third quarter. Two Sigma Investments LP now owns 14,192 shares of the biotechnology company’s stock valued at $736,000 after purchasing an additional 601 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Stock Performance
Enanta Pharmaceuticals stock opened at $14.74 on Friday. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $14.62 and a fifty-two week high of $67.45. The company has a market capitalization of $310.35 million, a P/E ratio of -2.34 and a beta of 0.37. The stock has a 50-day simple moving average of $18.17 and a 200-day simple moving average of $29.58.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. lowered Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and set a $14.00 target price for the company. in a report on Wednesday, August 9th. Jefferies Financial Group lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the company from $49.00 to $18.00 in a report on Tuesday, August 8th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $25.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, August 8th. Finally, JMP Securities decreased their price target on Enanta Pharmaceuticals from $65.00 to $42.00 and set a “market outperform” rating for the company in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $38.50.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Five stocks we like better than Enanta Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- How to Calculate Options Profits
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.